Epitheliotrophic capacity of serum eye drops from healthy donors versus serum from immunosuppressed patients with rheumatoid arthritis;Epitheliotrophe kapazität von serum-augentropfen gesunder versus immunsupprimierter patienten mit rheumatoider arthritis

Klinische Monatsblatter fur Augenheilkunde

Volumn 225, Issue 3, 2008, Pages 200-206

  Harloff, S ^a   Hartwig, D ^a   Kasper, K ^b   Wedel, T ^c   Muller M ^a   Geerling, Gerd ^b,d  

^a UNIVERSITY OF LÜBECK   (Germany)

^b UNIVERSITY OF WÜRZBURG   (Germany)

^c UNIVERSITY OF KIEL   (Germany)

^d UNIVERSITY HOSPITAL WÜRZBURG   (Germany)

Author keywords

Cornea; Epithelial defect; Immunosuppression; Rheumatoid arthritis; Serum

Indexed keywords

ALPHA TOCOPHEROL; AZATHIOPRINE; EPIDERMAL GROWTH FACTOR; EYE DROPS; FIBROBLAST GROWTH FACTOR; FIBRONECTIN; INTERLEUKIN 6; METHOTREXATE; PLATELET DERIVED GROWTH FACTOR AB; PREDNISOLONE; RETINOL; SCATTER FACTOR; TRANSFORMING GROWTH FACTOR BETA1;

ARTICLE; CELL CULTURE; CELL DIFFERENTIATION; CELL MIGRATION; CELL PROLIFERATION; CLINICAL ARTICLE; CONTROLLED STUDY; CORNEA DISEASE; CORNEA EPITHELIUM; ENZYME LINKED IMMUNOSORBENT ASSAY; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN CELL; IMMUNE DEFICIENCY; KERATINOCYTE; RHEUMATOID ARTHRITIS; SCANNING ELECTRON MICROSCOPY;

EID: 42149100589     PISSN: 00232165     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2008-1027199     Document Type: Article

References (32)

1. Alarcon GS, Schrohenloher RE, Bartolucci AA et al. Suppression of rheumatoid factor production by methotrexate in patients with rheumatoid arthritis. Evidence for differential influences of therapy and clinical status on IgM and IgA rheumatoid factor expression. Arthritis Rheum 1990; 33: 1156-1161
2. Araki-Sasaki K, Ohashi Y, Sasabe T et al. An SV40-immortalized human corneal epithelial cell line and its characterization. Invest Ophthalmol Vis Sci 1995; 36: 614-621
3. Badolato R, Oppenheim JJ. Role of cytokines, acute-phase proteins, and chemokines in the progression of rheumatoid arthritis. Semin Arthritis Rheum 1996; 26: 526-538
4. Barnard Z, Apel AJ, Harkin DG. Phenotypic analyses of limbal epithelial cell cultures derived from donor corneoscleral rims. Clin Experiment Ophthalmol 2001; 29: 138-142
5. Ferreira De Souza R, Kruse FE, Seitz B. Autologous serum for otherwise therapy resistant corneal epithelial defects - Prospective report on the first 70 eyes. Klin Monatsbl Augenheilkd 2001; 218: 720-726
6. Flour M, Degreef H. Pharmacological treatment of wounds. Semin Cutan Med Surg 1998; 17: 260-265
7. Fox RI, Chan R, Michelson JB et al. Beneficial effect of artificial tears made with autologous serum in patients with keratoconjunctivitis sicca. Arthritis Rheum 1984; 27: 459-461
8. Frantz A, Becker J. Establishing human, conjunctival fibroblast cultures as a test system for evaluating ophthalmic drugs. Klin Monatsbl Augenheilkd 1996; 208: 181-187
9. Geerling G, Daniels JT, Dart JK et al. Toxicity of natural tear substitutes in a fully defined culture model of human corneal epithelial cells. Invest Ophthalmol Vis Sci 2001; 42: 948-956
10. Herminghaus P, Geerling G, Hartwig D et al. Epitheliotrophic capacity of serum and plasma eyedrops. Influence of centrifugation. Ophthalmologe 2004; 101: 998-1005
11. Kanerud L, Engstrom GN, Tarkowski A. Evidence for differential effects of sulphasalazine on systemic and mucosal immunity in rheumatoid arthritis. Ann Rheum Dis 1995; 54: 256-262
12. Knorr M, Schuller S, Steuhl KP et al. EGF in therapy of corneal diseases. Principles and possible uses. Ophthalmologe 1992; 89: 119-127
13. Kruse FE, Tseng SC. Transforming growth factors beta 1 and 2 inhibit proliferation of limbus and corneal epithelium. Ophthalmologe 1994; 91: 617-623
14. Li Q, Weng J, Mohan RR et al. Hepatocyte growth factor and hepatocyte growth factor receptor in the lacrimal gland, tears, and cornea. Invest Ophthalmol Vis Sci 1996; 37: 727-739
15. Mcdonnell PJ, Schanzlin DJ, Rao NA. Immunoglobulin deposition in the cornea after application of autologous serum. Arch Ophthalmol 1988; 106: 1423-1425
16. Morgan GJ Jr, Chow WS. Clinical features, diagnosis, and prognosis in rheumatoid arthritis. Curr Opin Rheumatol 1993; 5: 184-190
17. Nelson JD. Much more than water. Br J Ophthalmol 1999; 83: 384-385
18. Neurath MF, Hildner K, Becker C et al. Methotrexate specifically modulates cytokine production by T cells and macrophages in murine collagen-induced arthritis (CIA): a mechanism for methotrexate-mediated immunosuppression. Clin Exp Immunol 1999; 115: 42-55
19. Pancholi S, Tullo A, Khaliq A et al. The effects of growth factors and conditioned media on the proliferation of human corneal epithelial cells and keratocytes. Graefes Arch Clin Exp Ophthalmol 1998; 236: 1-8
20. Poon AC, Geerling G, Dart JK et al. Autologous serum eyedrops for dry eyes and epithelial defects: clinical and in vitro toxicity studies. Br J Ophthalmol 2001; 85: 1188-1197
21. Prevoo ML, Van'T Hof MA, Kuper HH et al. Modified disease activity scores that include twenty-eight-joint counts. Development and validation in a prospective longitudinal study of patients with rheumatoid arthritis. Arthritis Rheum 1995; 38: 44-48
22. Rieck PW, Pleyer U. Corneal wound healing. II. Treatment of disorders of wound healing. Ophthalmologe 2003; 100: 1109-1130
23. Rohrbach JM, Steuhl KP, Knorr M et al. Ophthalmologische Traumatologie. Schattauer, 2002: 289-451
24. Sany J, Anaya JM, Canovas F et al. Influence of methotrexate on the frequency of postoperative infectious complications in patients with rheumatoid arthritis. J Rheumatol 1993; 20: 1129-1132
25. Sato M, Schneeweiss S, Scranton R et al. The validity of a rheumatoid arthritis medical records-based index of severity compared with the DAS28. Arthritis Res Ther 2006; 8: R57
26. Schultz G, Khaw PT, Oxford K et al. Growth factors and ocular wound healing. Eye 1994; 8 (Pt 2): 184-187
27. Singh G, Foster CS. Epidermal growth factor in alkali-burned corneal epithelial wound healing. Am J Ophthalmol 1987; 103: 802-807
28. Tsubota K, Goto E, Fujita H et al. Treatment of dry eye by autologous serum application in Sjogren's syndrome. Br J Ophthalmol 1999; 83: 390-395
29. Geerling G, Hartwig D. Autologe Serum-Augentropfen zur Therapie der Augenoberfläche - Eine Übersicht zur Wirksamkeit und Empfehlungen zur Anwendung. Ophthalmologe 2002; 99: 949-959
30. Liu L, Hartwig D, Harloff S et al. An optimized protocol for the production of autologous serum eyedrops. Graefe's Arch Clin Exp Ophthalmol 2005; 243: 706-714
31. Liu L, Hartwig D, Harloff S et al. Corneal epitheliotrophic capacity of three different blood-derived preparations. Inv Ophthalmol Vis Sci 2006; 47 (6): 2438-2444
32. Schrader S, Wedel T, Moll R et al. Combination of serum eye drops with hydrogel bandage contact lenses in the treatment of persistent epithelial defects. Graefe's Arch Clin Exp Ophthalmol 2006; 244: 1345-1349